Astellas Pharma (OTCMKTS:ALPMY) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to MarketBeat, Astellas Pharma presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Trading Up 1.4%

OTCMKTS ALPMY opened at $13.35 on Tuesday. Astellas Pharma has a 12 month low of $9.22 and a 12 month high of $17.35. The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23. The stock’s fifty day moving average price is $14.31 and its 200-day moving average price is $14.65. The stock has a market cap of $24.16 billion, a P/E ratio of 12.43 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Monday, April 27th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.19 by $0.14. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. As a group, equities analysts forecast that Astellas Pharma will post 1.34 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).